Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study

Journal of Geriatric Psychiatry and Neurology

Volumn 9, Issue 1, 1996, Pages 1-6

  Kaufer, Daniel I ^a   Cummings, Jeffrey L ^a,b   Christine, Dianne ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACRINE;

AGED; ALZHEIMER DISEASE; ANXIETY; APATHY; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HALLUCINATION; HUMAN; LOCOMOTION; MALE; PRIORITY JOURNAL;

EID: 0029914548     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198879600900101     Document Type: Article

References (31)

1. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215:1237-1239.
2. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in dementia. B M J Clin Res 1978; 2:1457-1459.
3. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 1986; 19:1-28.
4. Bartus RT, Dean III RL, Beer B, Lippa A. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-417.
5. Perry EK. The cholinergic hypothesis - ten years on. Br Med Bull 1986; 42:63-69.
6. Jenike MA, Albert M, Baer L, Gunther J. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial. J Geriatr Psychiatry Neurol 1990; 3:13-16.
7. Schneider LS. Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology 1994; 43(Suppl 4):S64-S79.
8. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991; 337:989-992.
9. Davis K, Thai L, Gamzu E, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327:1253-1259.
10. Farlow M, Gracon S, Hershey L, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268:2523-2528.
11. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271:985-991.
12. Chatellier G, Lacomblez L, on behalf of Groupe Français d'Etude de la Tetrahydroaminoacridine. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. B M J 1990; 300:95-499.
13. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease: results of a Canadian double-blind, cross-over, multicenter study. N Engl J Med 1990; 322:1272-1276.
14. Cummings JL, Victoroff JI. Noncognitive neuropsychiatric syndromes in Alzheimer's disease. Neuropsychiatry, Neuropsychol Behav Neurol 1990; 3:140-158.
15. Mangone CA, Sanguinetti RM, Baumann PD, et al. Influence of feelings of burden on the caregiver's perception of the patient's functional status. Dementia 1993; 4:287-293.
16. Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer's type and age-matched controls. Arch Gen Psychiatry 1987; 44:418-426.
17. Penn RD, Martin EM, Wilson RS, et al. Intraventricular bethanecol infusion for Alzheimer's disease: results of double-blind and escalating dose trials. Neurology 1988; 8:219-222.
18. Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993; 33:536-541.
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease. Neurology 1984; 34:939-944.
20. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
22. Salmon DP, Thai LJ, Butters N, et al. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of three standardized mental status examinations. Neurology 1990; 40:1225-1230.
23. Rosen WG, Mohs, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.
24. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48(Suppl 5):9-15.
25. Meer B, Baker JA. The Stockton Geriatric Rating Scale. J Gerontology 1966; 21:392-403.
26. Sarter M. Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin? Psychopharmacology 1994; 114:539-550.
27. Szymusiak R. Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. Sleep 1995; 18:478-500.
28. Decker MW, McGaugh JL. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991; 7:151-168.
29. Alhainen K, Helkala E-L, Reinikainen K, Riekkinen P Sr. The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J Neural Transm [P-D Sect] 1993; 5:185-192.
30. Adem A, Jossan SS, Oreland L. Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase. Neurosci Lett 1989; 107:313-317.
31. Raskind MA, Peskind ER. Neurobiologic bases of noncognitive behavioral problems in Alzheimer's disease. Alzheimer Dis Assoc Disord 1994; 8(Suppl 3):54-60.